ofatumumab

FDA Drug Profile — KESIMPTA

Drug Details

Generic Name
ofatumumab
Brand Names
KESIMPTA
Application Number
BLA125326
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
2
Dosage Forms
LIQUID, INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
OFATUMUMAB

Indications and Usage

1 INDICATIONS AND USAGE KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )